Centracare Kidney Program At Princeton is a medicare approved dialysis facility center in Princeton, Minnesota and it has 9 dialysis stations. It is located in Mille Lacs county at 112 S Rum River Dr, Suite 10, Princeton, MN, 55371. You can reach out to the office of Centracare Kidney Program At Princeton at (763) 389-7969. This dialysis clinic is managed and/or owned by Centracare Dialysis. Centracare Kidney Program At Princeton has the following ownership type - Non-Profit. It was first certified by medicare in December, 2000. The medicare id for this facility is 243526 and it accepts patients under medicare ESRD program.
| Name | Centracare Kidney Program At Princeton |
|---|---|
| Location | 112 S Rum River Dr, Suite 10, Princeton, Minnesota |
| No. of Dialysis Stations | 9 |
| Medicare ID | 243526 |
| Managed By | Centracare Dialysis |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 112 S Rum River Dr, Suite 10, Princeton, Minnesota, 55371 | |
| (763) 389-7969 | |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
| NPI Number | 1730138223 |
| Organization Name | Centracare Kidney Program - Princeton Dialysis |
| Doing Business As | St Cloud Hospital |
| Address | 112 South Rum River Drive Princeton, Minnesota, 55371 |
| Phone Number | (763) 389-7969 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 12 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 29 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 259 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Centracare Kidney Program At Princeton with elevated calcium levels.
| Patients with hypercalcemia | 29 |
| Hypercalcemia patient months | 260 |
| Patients with Serumphosphor | 30 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 33 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 38 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 4 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 22 |
| Patient months included in arterial venous fistula and catheter summaries | 187 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 68 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 17 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 22 |
| Hospitalization Rate in facility | 177.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 402.8 |
| Hospitalization Rate: Lower Confidence Limit | 83.3 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at Centracare Kidney Program At Princeton were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 25.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 41.9 |
| Readmission Rate: Lower Confidence Limit | 11.8 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Centracare Kidney Program At Princeton get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .48 (As Expected) |
| SIR: Upper Confidence Limit | 2.36 |
| SIR: Lower Confidence Limit | .02 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Centracare Kidney Program At Princeton's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 21 |
| Transfusion Rate in facility | 41.1 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 174 |
| Transfusion Rate: Lower Confidence Limit | 11.6 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at Centracare Kidney Program At Princeton lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 102 |
| Mortality Rate in facility | 9.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 18.2 |
| Mortality Rate: Lower Confidence Limit | 4.8 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago
Centracare Kidney Program At Princeton Location: 112 S Rum River Dr, Suite 10, Princeton, Minnesota, 55371 Phone: (763) 389-7969 |
News Archive
Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.
Comprehensive Care Corporation today reported results for the first quarter ended March 31, 2011.
Isotechnika Pharma Inc. announced today that Lux Biosciences, Inc. has commenced its pivotal Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability.
Every high school biology class learns about the tiny cells that comprise our bodies, as well as about many of the diverse actions that they perform.
Using a unique computational approach to rapidly sample, in millisecond time intervals, proteins in their natural state of gyrating, bobbing, and weaving, a research team from UC San Diego and Monash University in Australia has identified promising drug leads that may selectively combat heart disease, from arrhythmias to cardiac failure.
› Verified 1 days ago